Back to Directory

Rebecca Dirschberger

Email

dirsch@frontierscience.org

Phone

716-834-0900 ext. 7268

Institution

Frontier Science Foundation

Address

Frontier Science Foundation
4033 Maple Road
Amherst, NY 14226

Request an Update

Affiliated Studies

IMPAACT 2051: Phase II Study of the Pharmacokinetics, Safety, Tolerability, and Anti-Mycobacterial Activity of Pretomanid with Bedaquiline, Linezolid, with or without Moxifloxacin (BPaL/M) in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

Research Area

Study Status

IMPAACT 2050: Phase IV Study of the Pharmacokinetics of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV in the United States

DAIDS Number

Research Area

Study Status

IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV

DAIDS Number

Research Area

Study Status

Closed to Follow Up

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

DAIDS Number

Research Area

Brain and Mental Health

Study Status

Participants Off Study and Primary Analysis Completed

P1090: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine

DAIDS Number

Research Area

Study Status

Show All